ADVANCE
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 462 patients (estimated)
- Sponsors
- Sylvester Comprehensive Cancer Center (Main)
- Collaborators
- Amgen
- Tags
- Monoclonal Antibody, CD38
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1072
- NCT Identifier
- NCT04268498
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.